Form 4: Xilio Therapeutics Director Daniel Curran Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director Daniel J. Curran was granted 31,000 stock options with an exercise price of $0.693 per share, vesting fully by June 11, 2026, or the next annual meeting.

Summary

• Daniel J. Curran, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options on June 11, 2025.
• The options have an exercise price of $0.693 per share.
• The options will vest as to 100% of the shares on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Curran's continued service to Xilio Therapeutics through the vesting date.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Curran beneficially owns 31,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a disclosure of an insider transaction, the grant of options to a director indicates continued alignment of interests and commitment to the company's future, which is generally viewed favorably by investors. It does not, however, provide new operational or financial performance data.

Positives

• The grant of stock options to Director Daniel J. Curran aligns his interests with those of shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period (until June 10, 2035), providing a long-term incentive for the director.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, beyond the vesting schedule of the granted options.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of 31,000 stock options to a director is a standard form of equity compensation in the biotech sector, comparable to practices at similar-sized companies like 'Aileron Therapeutics' or 'Oncorus, Inc.' (prior to their respective corporate actions), where director compensation often includes a mix of cash and equity incentives.
• The exercise price of $0.693 is based on the market price at the time of grant, which is typical for incentive stock options.
• The vesting schedule, tied to continued service and an annual meeting, is a common mechanism to ensure director retention and commitment, similar to compensation structures seen at companies such as 'Foghorn Therapeutics' or 'Vaxcyte, Inc.' for their non-employee directors.

Related Party Transactions

• The grant of stock options to Daniel J. Curran, a Director of Xilio Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to Daniel J. Curran's continued service.

Key Dates

Recommendation

Keywords

Xilio Therapeutics, XLO, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Biotechnology, Pharmaceuticals